Weekly Disease Surveillance Report

2021 Reporting Week 42: October 17 – October 23

This weekly report is produced by the DOH-Okaloosa Epidemiology Section to provide situational awareness to community partners. Data is subject to change as additional information is gathered.

Influenza (Flu) and COVID-19 Steady

Influenza-like illness (ILI) activity in Okaloosa remained elevated this past week at 3.0%, double what we normally see this time of year (average 1.5%). We continue to encourage providers to review CDC's <u>Seasonal Influenza Vaccination Resources for Health Professionals</u> to be prepared for counseling on co-administration of COVID-19 and flu vaccines, patient education, and the 2021-22 flu vaccine composition.

This week's COVID-19 community risk level remains at SUBSTANTIAL. The total number of Okaloosa residents aged 12 and older that are fully-vaccinated continues to rise and has currently at 61.4% - that's 109,618 individuals! Please continue to encourage vaccination as the COVID-19 vaccine is highly effective at preventing severe disease and death.

COVID-19 Booster Shots and Monoclonal Antibody Resources

On October 21, 2021, the <u>CDC Expanded Eligibility for COVID-19 Booster Shots</u>. The CDC recommends that certain people are now eligible to receive a COVID-19 **booster** shot, including those who received Moderna and J&J/Janssen COVID-19 vaccines. Please see <u>page 6</u> for the COVID-19 Vaccine Booster Update from the Florida Department of Health dated October 25, 2021, which expands on this CDC guidance.

Additionally, CDC continues to recommend that <u>moderately and severely immunosuppressed people</u> who completed either the Moderna or Pfizer vaccine series get a **third dose** of the same mRNA vaccine at least 28 days after the second dose as they may not build the same level of immunity to 2-dose vaccine series compared to people who are not immunocompromised.

FREE <u>Monoclonal Antibody Treatments</u> are available in Okaloosa for use in adult and pediatric patients (12 and older) who have either been diagnosed or exposed to someone with COVID-19 and are at high risk for progression to severe illness, hospitalization, or death from COVID-19. Please follow the link for all locations.

Contact Us:

Florida Department of Health in Okaloosa County

Epidemiology Section

24/7 Disease Reporting: 850-833-9065

Confidential Fax: 850-833-7577 <u>okaloosaepi@flhealth.gov</u>

COVID-19 Snapshot

Week 42 Review		Difference from Wk41
Resident Case Count	125	-23
Resident Case Count per 100K Population	60.6	-11.1
Average Resident Cases per Day	17.9	-3.2
Percent Positivity	5.5%	0%
	Data Sourco	Marlin Natahasa

Data Source: Merlin Database

The Florida Department of Health (FDOH) provides the Centers for Disease Control and Prevention (CDC) with county COVID-19 data, including deaths.

Please visit the <u>COVID-19 Community Profile Report</u> webpage to obtain death data by downloading the most recent excel file and locating Okaloosa on the 'Counties' tab.

For questions related to COVID-19 death data, please contact the FDOH Office of Communications at 850-245-4111 or <u>NewsMedia@flhealth.gov</u>.

Week 42 Community Risk Level

COVID-19 Community	New Cases per 100K	% Positivity
Risk Level	Population per Week	per Week
SUBSTANTIAL	60.6	5.5%


PREVIOUS WEEK RISK LEVEL: SUBSTANTIAL

Low	<10	<5%
Moderate	10-49	5-7.9%
Substantial	50-99	8-9.9%
	>100	>10%

Community risk level is the color of the higher risk level for the two indicators. Data Source : CDC Community Indicators at the County Level







COVID-19 Fully Vaccinated = No Quarantine




Figure 2: Trend of COVID-19 case rates by week. Data source: Merlin Database




Figure 3: Trend of 7-day moving percent positivity of COVID-19 cases by week. Data source: Merlin Database

COVID-19 Cases by Age Group

			-
Age Group	Okaloosa Resident Cases since 03/01/21 through Week 42	% by Age Group	Difference from Week 41
0-11	2021	13.0%	+13
12-14	703	4.5%	+5
15-24	2391	15.4%	+6
25-44	5329	34.2%	+43
45-64	3564	22.9%	+41
65-74	954	6.1%	+10
75-84	394	2.5%	+5
85+	206	1.3%	+2
Unknown	6	0.0%	0
Total	15568	100%	+125

Data Source: Merlin Database

COVID-19 in Okaloosa County

Week 42: October 17 - October 23

COVID-19 in Okaloosa County

Week 42: October 17 - October 23

IMPACT OF COVID-19 VACCINATION IN OKALOOSA




Figure 4: Cumulative number of fully vaccinated Okaloosa residents as compared to COVID-19 cases per week. Data reported through previous Sunday. Data Source: Merlin & CDC <u>COVID Data Tracker</u>

VACCINATION DATA RESOURCE

The CDC COVID Data Tracker presents county level vaccination data that includes vaccinations from:

COVID-19 Fully Vaccinated = No Quarantine

- FL SHOTS, including FL Department of Health, retail pharmacies, and long-term care facilities,
- Dialysis centers participating in the Federal Dialysis Center Program,
- Health Resources and Services Administration partner sites, and
- Federal entities such as Department of Defense, Veterans Health Administration, Indian Health Service and Bureau of Prisons.



Data Source: Merlin & CDC <u>COVID Data Tracker</u>

COVID-19 VACCINATIONS


Fully-Vaccinated Groups	OKALOOSA	US
% of Population \geq 12 Years of Age	61.4%	67.2%
% of Population \ge 18 Years of Age	63.9%	68.9%
% of Population \ge 65 Years of Age	88.6%	84.7%

Data reported through previous Sunday. Data Source: CDC <u>COVID Data Tracker</u>

Influenza-Like Illness

Week 42: October 17 - October 23

Influenza-like Illness (ILI) is defined as fever greater than or equal to 100°F AND cough and/or sore throat in the absence of another known cause.



ANALYSIS: During Week 42, flu reporting partners and ESSENCE (a syndromic surveillance system) reported a plateau in ILI activity for Okaloosa County. The percentage of ILI ED visits in Okaloosa County remained steady from 3.03 % during Week 41 to 3.00% during Week 42. Flu partners reported no positive rapid influenza tests this week. Over the past three weeks, 19 out of 176 influenza specimens submitted to the state lab were positive (8 Influenza A unspecified, 11 Influenza B unspecified). There were no ILI admissions, outbreaks, or deaths reported this week. The percentage of total ILI ED visits for Week 42 is higher than that of Week 42 last year.

Note: Other respiratory syndromes can be represented by increased ILI case numbers. Data Source: ESSENCE

% ILI by Age Group Week 42, 2021			
Age Range	ILI Visits	Total ED Visits	% Total ILI Visits
0-4	28	217	12.90%
5-19	18	315	5.71%
20-34	7	485	1.44%
35-54	10	533	1.88%
55-74	2	485	0.41%
75+	4	266	1.50%






Figure 6: Hospital ED visits meeting ILI criteria stratified by facility. Percentages calculated based on total number of ILI ED visits. (n=69). Data source: ESSENCE


Data Source: ESSENCE


Syndromic Surveillance

Week 42: October 17 - October 23









Data source: ESSENCE

Week 42—Fort Walton Beach Medical Center


Age Range	Top Syndrome	Total ED Visits for Syndrome
0-4	FEVER	54
5-19	RESP	26
20-34	INJURY	47
35-54	INJURY	41
55-74	GI	32
75+	INJURY	23

Week 42—North Okaloosa Medical Center


Age Range	Top Syndrome	Total ED Visits for Syndrome
0-4	RESP	12
5-19	INJURY	8
20-34	GI	13
35-54	INJURY	11
55-74	GI	16
75+	GI, INJURY	10, 10

Syndromic Surveillance

Week 42: October 17 - October 23



Week 42—Twin Cities Hospital		
Age Range	Top Syndrome	Total ED Visits for Syndrome
0-4	FEVER, RESP	4, 4
5-19	RESP	14
20-34	INJURY	10
35-54	GI	16
55-74	INJURY	16
75+	INJURY	9



Week 42—DestinER		
Age Range	Top Syndrome	Total ED Visits for Syndrome
0-4	RESP	5
5-19	RESP	6
20-34	INJURY	5
35-54	GI, INJURY	5, 5
55-74	INJURY	7
75+	RESP	4

Week 42—Okaloosa County	
Age Group	Top Syndrome
0-4	RESP
5-19	RESP
20-34	INJURY
35-54	INJURY
55-74	INJURY
75+	INJURY
	Data Source: ESSENCE





Joseph A. Ladapo, MD, PhD State Surgeon General

Vision: To be the Healthiest State in the Nation

October 25, 2021

COVID-19 Vaccine Booster Update

On October 21, 2021, the Advisory Committee on Immunizations Practices (ACIP) recommended the use of COVID-19 vaccination boosters for both the Moderna COVID-19 vaccine and Janssen COVID-19 vaccine (Johnson and Johnson) under the current emergency use authorization. Pfizer-BioNTech COVID-19 vaccine boosters were previously recommended by ACIP on September 24, 2021.

- Pfizer-BioNTech and Moderna COVID-19 booster vaccines are currently recommended for individuals 18 years of age and older who have completed their initial COVID-19 vaccination series, at least 6 months have passed since the completion of their second dose and they meet one of the following criteria:
 - o 65 years or older
 - Reside in a long-term care facility
 - 18-64 years of age with underlying medical condition(s)
 - 18-64 years of age with increased risk for COVID-19 exposure and transmission because of occupational or institutional setting
- Janssen (Johnson and Johnson) COVID-19 booster vaccines are currently recommended for individuals who have received their initial COVID-19 vaccination and at least two months have passed since their initial dose.

There are now booster recommendations for all three available COVID-19 vaccines in the United States. Eligible individuals may choose which vaccine they receive as a booster dose, when available. Some individuals may have a preference for the vaccine type that they originally received, while others may prefer to get a different booster. The Center for Disease Control and Prevention's recommendations now allow for this type of mix and match dosing for booster shots of COVID-19 vaccine.

For additional information regarding COVID-19 vaccine boosters, visit <u>https://www.cdc.gov/media/releases/2021/p1021-covid-booster.html</u>.

